Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class therapies ...

Abstract: We study the performance behavior of the sparse matrix-vector product operation in distributed computing environments, in the case of very large non-diagonal matrices where the nonzero ...

The FDA today unveiled a plan to accelerate development of biosimilars in hopes of significantly reducing drug costs in the United States.

Abstract: We propose a photonic computing core that supports simultaneous parallel computing of two independent matrix-vector multiplications, with an ultra-compact ...